Document Classification

Section Type: METHODS

Text: In this randomized, observer-blinded study, adults 18 years of age (n = 841) received 3. 75 or 7. 5 g hemagglutinin antigen (HA) of an AS03-adjuvanted (AS03A or AS03B) A/Indonesia/5 / 2005 H5N1 (subclade 2. 1) vaccine (priming), followed by the same HA dose of AS03-adjuvanted A/turkey/Turkey / 1/05 H5N1 (clade 2. 2) influenza vaccine as a booster 6 or 18 months after priming ; an unprimed group received placebo at Day 0, and 3. 75 g HA of AS03A-adjuvanted booster vaccine at 6 and 18 months.